Carisma Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Carisma Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2014 to Q3 2024.
  • Carisma Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.12M, a 31.5% increase year-over-year.
  • Carisma Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $3.67M, a 147% increase year-over-year.
  • Carisma Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.32M, a 742% increase from 2022.
  • Carisma Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $275K, a 94.7% decline from 2021.
  • Carisma Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5.14M, a 193% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.67M $1.12M +$267K +31.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $3.4M $625K +$295K +89.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $3.11M $1.06M +$792K +299% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.32M $873K +$833K +2083% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 $1.48M $848K +$760K +864% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $723K $330K +$272K +469% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $451K $265K +$176K +198% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $275K $40K -$1.72M -97.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 $1.99M $88K -$1.08M -92.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $3.07M $58K -$1.2M -95.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $4.27M $89K -$869K -90.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.14M $1.76M +$1.35M +333% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $3.79M $1.17M +$715K +158% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $3.08M $1.26M +$768K +156% Apr 1, 2021 Jun 30, 2021 10-Q/A 2022-08-25
Q1 2021 $2.31M $958K +$551K +135% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $1.76M $406K +$79K +24.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $1.68M $453K +$224K +97.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $1.45M $491K +$136K +38.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $1.32M $407K +$81K +24.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.24M $327K -$434K -57% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $1.67M $229K -$19K -7.66% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $1.69M $355K +$292K +463% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $1.4M $326K +$115K +54.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $1.28M $761K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-15
Q3 2018 $248K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $63K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $211K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q3 2016 $1.7M +$1.7M Sep 20, 2016 10-K 2019-03-01
Q3 2015 $0 -$272K -100% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-04
Q2 2015 $0 -$5K -100% Apr 1, 2015 Jun 30, 2015 10-Q 2015-08-13
Q1 2015 $0 -$17K -100% Jan 1, 2015 Mar 31, 2015 10-Q 2015-04-30
Q3 2014 $272K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-04
Q2 2014 $5K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 $17K Jan 1, 2014 Mar 31, 2014 10-Q 2015-04-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.